A Phase 2 interventional study of EGT0001442 and Placebo in Diabetes Mellitus, sponsored by Theracos. Completed at 11 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-07-01.
Sponsored by Theracos · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,022 studies in Diabetes Mellitus with a site in United States — 288 open to participants now, 388 under way, 12 of them phase 3. Diabetes Mellitus · United States.
Among the 3,022 studies in Diabetes Mellitus with a site in United States, this one is the 609th largest by enrollment of the 2,501 interventional ones that give a count, is one of 147 that started in 2011, is one of 279 in phase 2, and was the 1,164th registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →288 of the 3,022 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
Wayne State University · Sites in United States
Ages 16–20
Mayo Clinic · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,022 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 262 · Phase 2 371 · Phase 3 340 · Phase 4 215
First in 1976; this study’s year is marked. 147 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 288 is above the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 82 across the 2,501 interventional studies, 159 across the 499 observational. Of the 2,398 that completed or were terminated, 990 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
852 of 3,022 have an industry lead sponsor. The 10 most frequent:
Theracos is the lead sponsor of 21 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 9 (100%) have results posted.
Theracos has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
139 of the studies in Diabetes Mellitus with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03982693Phase 3Mt. Sinai Medical Center, MiamiTrial to Assess Chelation Therapy in Critical Limb Ischemia | 2026-12 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07556354University of Alabama at BirminghamEmpowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City | 2026-11 |
Add all 139 to your calendar (.ics) → With an account.
Among the 3,022 studies in Diabetes Mellitus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy of EGT0001442 in lowering glycosylated Hemoglobin (HbA1c, A laboratory test to diagnose three months average of blood sugar)levels at 24th week from baseline, when compared to placebo group(no diabetic medication given). The secondary aim of the study is to evaluate the efficacy of EGT0001442 in lowering fasting blood glucose at the weeks 2 and 24 and comparing the results with placebo group. This study assess the efficacy of EGT0001442 based on the proportion of subjects who reach the American Diabetes Association (ADA) target of HbA1c of \< 7% in EGT0001442 group and comparison with placebo. The study also evaluates the effect of EGT0001442 on systolic, diastolic pressures, body weight and compare with the respective placebo groups.This study also assess the change from baseline in HbA1c overtime, from week 1 to week 96. Finally, to assess the safety of EGT0001442 in the Type 2 Diabetic patients (adult/maturity onset).
EGT0001442 is a compound that may inhibit the effect of other compounds in the body known as sugar transporters. The use of EGT0001442 may enhance the elimination of glucose from the blood by increasing the amount of urine produced. Hence the blood glucose levels are significantly decreased and the efficacy of EGT001442 can be established by assessing the three months average blood glucose levels (HbA1c). Due to the increased urinary output, the effect of EGT001442 on blood pressure levels are also assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EGT0001442 capsule, 20 mg, daily, 96 weeks
Drug: EGT0001442
Placebo
Drug: Placebo
Also known as: Bexagliflozin
Change From Baseline in Hemoglobin A1c at 24 Weeks
Changes from baseline in HbA1c in placebo and treatment group at end of 24 weeks treatment
Time frame: Baseline and Week 24
Changes in Systolic and Diastolic Blood Pressure at Week 24
Changes from baseline in systolic and diastolic blood pressure in placebo and treatment group after 24 weeks of treatment
Time frame: Baseline and Week 24
Changes in Body Weight at Week 24
Changes from baseline in body weight in placebo and treatment group after 24 weeks of treatment
Time frame: Baseline and week 24
Change From Baseline in HbA1c Over 96 Weeks Time
Change from baseline in HbA1c level over 96 weeks in placebo and treatment group. The treatment group was treated with EGT0001442 for 24 weeks.
Time frame: Baseline and up to 96 weeks
Change From Baseline Over Time in Fasting Plasma Glucose (FPG)
Changes from baseline in FPG in placebo and treatment group over 24 weeks of treatment
Time frame: 24 weeks
Percentage of Subjects Achieving HbA1c <7%
The number and percentage of subjects achieving HbA1c response levels \<7% for the FAS using LOCF is reported
Time frame: Baseline and up to 96 weeks
| Milestone | EGT0001442 | Placebo |
|---|---|---|
| Started | 145 | 143 |
| Safety population | 145 | 141 |
| Completed | 109 | 108 |
| Not completed | 36 | 35 |
| Withdrew: Withdrawal by subject | 25 | 28 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Physician decision | 6 | 3 |
| Withdrew: Study terminated by sponsor | 0 | 1 |
Changes from baseline in HbA1c in placebo and treatment group at end of 24 weeks treatment
| percentage of glycated hemoglobin | EGT0001442 | Placebo |
|---|---|---|
| Change From Baseline in Hemoglobin A1c at 24 Weeks | -0.28 ± 0.194 | 0.51 ± 0.200 |
Changes from baseline in systolic and diastolic blood pressure in placebo and treatment group after 24 weeks of treatment
| mm Hg | EGT0001442 | Placebo |
|---|---|---|
| Systolic blood pressure | -8.62 ± 1.903 | -3.08 ± 1.964 |
| Diastolic blood pressure | -3.07 ± 1.223 | -0.40 ± 1.275 |
Changes from baseline in body weight in placebo and treatment group after 24 weeks of treatment
| kg | EGT0001442 | Placebo |
|---|---|---|
| Changes in Body Weight at Week 24 | -2.95 ± 0.555 | -1.22 ± 0.592 |
Change from baseline in HbA1c level over 96 weeks in placebo and treatment group. The treatment group was treated with EGT0001442 for 24 weeks.
| percentage glycated hemoglobin | EGT0001442 | Placebo |
|---|---|---|
| Week 2 | -0.10 ± 0.083 | 0.22 ± 0.084 |
| Week 6 | -0.11 ± 0.137 | 0.49 ± 0.141 |
| Week 12 | -0.19 ± 0.180 | 0.53 ± 0.186 |
| Week 18 | -0.28 ± 0.195 | 0.43 ± 0.201 |
| Week 24 | -0.28 ± 0.194 | 0.51 ± 0.200 |
| Week 36 | -0.52 ± 0.202 | 0.42 ± 0.209 |
| Week 48 | -0.45 ± 0.215 | 0.54 ± 0.222 |
| Week 60 | -0.57 ± 0.219 | 0.41 ± 0.226 |
| Week 72 | -0.43 ± 0.213 | 0.50 ± 0.220 |
| Week 84 | -0.60 ± 0.218 | 0.38 ± 0.225 |
| Week 96 | -0.48 ± 0.215 | 0.54 ± 0.222 |
Changes from baseline in FPG in placebo and treatment group over 24 weeks of treatment
| mmol/L | EGT0001442 | Placebo |
|---|---|---|
| Week 2 | -1.39 ± 0.407 | 0.85 ± 0.422 |
| Week 6 | -1.23 ± 0.482 | 1.22 ± 0.499 |
| Week 12 | -1.75 ± 0.489 | 0.67 ± 0.507 |
| Week 18 | -1.87 ± 0.451 | 0.83 ± 0.467 |
| Week 24 | -1.74 ± 0.462 | 0.89 ± 0.478 |
The number and percentage of subjects achieving HbA1c response levels \<7% for the FAS using LOCF is reported
| Participants | EGT0001442 | Placebo |
|---|---|---|
| Week 2 | 14 | 13 |
| Week 6 | 22 | 15 |
| Week 12 | 27 | 17 |
| Week 18 | 29 | 14 |
| Week 24 | 33 | 14 |
| Week 36 | 35 | 14 |
| Week 48 | 41 | 20 |
| Week 60 | 39 | 18 |
| Week 72 | 39 | 17 |
| Week 84 | 43 | 16 |
| Week 96 | 44 | 14 |
Collected over The adverse event data were collected from Week 0 (Visit 3) up to Week 97 (Visit 15, 1 week follow-up after completion of study).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EGT0001442 | 1/145 (0.7%) | 3/145 (2.1%) | 50/145 (34.5%) |
| Placebo | 0/141 (0%) | 12/141 (8.5%) | 62/141 (44%) |
| Event | EGT0001442 | Placebo |
|---|---|---|
| CellulitisInfections and infestations | 2/145 | 0/141 |
| TachycardiaCardiac disorders | 0/145 | 1/141 |
| Hypertensive crisisCardiac disorders | 0/145 | 1/141 |
| Respiratory disorderRespiratory, thoracic and mediastinal disorders | 0/145 | 1/141 |
| PneumoniaInfections and infestations | 0/145 | 1/141 |
| Urinary tract infectionInfections and infestations | 0/145 | 1/141 |
| Herpes zosterInfections and infestations | 0/145 | 1/141 |
| Tonsil cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/145 | 1/141 |
| Spinal column stenosisNervous system disorders | 0/145 | 1/141 |
| Peripheral nerve lesionNervous system disorders | 0/145 | 1/141 |
| Event | EGT0001442 | Placebo |
|---|---|---|
| Urinary Tract InfectionInfections and infestations | 17/145 | 28/141 |
| HypoglycemiaMetabolism and nutrition disorders | 24/145 | 24/141 |
| HeadacheNervous system disorders | 7/145 | 9/141 |
| DyslipidaemiaMetabolism and nutrition disorders | 5/145 | 8/141 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 5/145 | 8/141 |
| Age, Continuous(years) | EGT0001442 | Placebo | Total |
|---|---|---|---|
| Mean | 56.2 ± 10.94 | 54.7 ± 10.30 | 55.4 ± 10.64 |
| Sex: Female, Male(Participants) | EGT0001442 | Placebo | Total |
|---|---|---|---|
| Female | 78 | 91 | 169 |
| Male | 67 | 50 | 117 |
| Ethnicity (NIH/OMB)(Participants) | EGT0001442 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 129 | 125 | 254 |
| Not Hispanic or Latino | 16 | 16 | 32 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | EGT0001442 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 5 |
| White | 110 | 112 | 222 |
| More than one race | 31 | 25 | 56 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body Mass Index(kg/m2) | EGT0001442 | Placebo | Total |
|---|---|---|---|
| Mean | 29.7 ± 5.35 | 30.6 ± 5.41 | 30.1 ± 5.39 |
| Baseline HbA1c Category(Participants) | EGT0001442 | Placebo | Total |
|---|---|---|---|
| < 8.5% | 87 | 100 | 187 |
| > 8.5% | 58 | 41 | 99 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Dec 2011, a primary completion of Nov 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2021, 7 years 7 months after primary completion. A results delay was requested in Jul 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bexagliflozin
Theracos